Immuron is a biotechnology company based in Melbourne, Australia.[1] In 2008, the company changed its name to Immuron Limited,[2] having previously operated as Anadis Limited.[3][4]

Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases.. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea (TD) and Anthrax containment.

In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market.[5]

References

  1. ↑ "Anadis". Australian Stock Exchange. 5 June 2007.
  2. ↑ "About Us". immuron1. Retrieved 7 May 2022.
  3. ↑ "Immuron Limited - ABN, ACN, Business names, Former names". www.aubiz.net. Retrieved 7 May 2022.
  4. ↑ "IMMURON LIMITED - Australia Company". australia-corp.com. Retrieved 7 May 2022.
  5. ↑ Canada, Asia Pacific Foundation of. "Valeo Pharma, Baralex Sign Distribution Agreement with Australia's Anadis Ltd". Asia Pacific Foundation of Canada. Retrieved 18 September 2017.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.